Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Retained Earnings: 2021-2024

Historic Retained Earnings for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Dec 2024 value amounting to -$606.7 million.

  • Amylyx Pharmaceuticals' Retained Earnings fell 26.23% to -$718.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$718.4 million, marking a year-over-year decrease of 26.23%. This contributed to the annual value of -$606.7 million for FY2024, which is 98.95% down from last year.
  • Latest data reveals that Amylyx Pharmaceuticals reported Retained Earnings of -$606.7 million as of FY2024, which was down 98.95% from -$304.9 million recorded in FY2023.
  • Amylyx Pharmaceuticals' 5-year Retained Earnings high stood at -$155.8 million for FY2021, and its period low was -$606.7 million during FY2024.
  • Its 3-year average for Retained Earnings is -$422.0 million, with a median of -$354.2 million in 2022.
  • Per our database at Business Quant, Amylyx Pharmaceuticals' Retained Earnings slumped by 127.29% in 2022 and then climbed by 13.91% in 2023.
  • Amylyx Pharmaceuticals' Retained Earnings (Yearly) stood at -$155.8 million in 2021, then crashed by 127.29% to -$354.2 million in 2022, then grew by 13.91% to -$304.9 million in 2023, then crashed by 98.95% to -$606.7 million in 2024.